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Abstract
Background: Recently there has been a significant increase in the number of systematic reviews addressing 
questions of prevalence. Key features of a systematic review include the creation of an a priori protocol, clear 
inclusion criteria, a structured and systematic search process, critical appraisal of studies, and a formal process 
of data extraction followed by methods to synthesize, or combine, this data. Currently there exists no standard 
method for conducting critical appraisal of studies in systematic reviews of prevalence data.
Methods: A working group was created to assess current critical appraisal tools for studies reporting prevalence 
data and develop a new tool for these studies in systematic reviews of prevalence. Following the development of 
this tool it was piloted amongst an experienced group of sixteen healthcare researchers. 
Results: The results of the pilot found that this tool was a valid approach to assessing the methodological 
quality of studies reporting prevalence data to be included in systematic reviews. Participants found the tool 
acceptable and easy to use. Some comments were provided which helped refine the criteria.
Conclusion: The results of this pilot study found that this tool was well-accepted by users and further 
refinements have been made to the tool based on their feedback. We now put forward this tool for use by 
authors conducting prevalence systematic reviews.
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Introduction
The prevalence of a disease indicates the number of people 
in a population that have the disease at a given point in time 
(1). The accurate measurement of disease burden among 
populations, whether at a local, national, or global level, 
is of critical importance for governments, policy-makers, 
health professionals and the general population to inform the 
development, delivery and use of health services. For example, 
accurate information regarding measures of disease can assist 
in planning management of disease services (by ensuring 
sufficient resources are available to cope with the burden of 
disease), set priorities regarding public health initiatives, and 
evaluate changes and trends in diseases over time. However, 
policy-makers are often faced with conflicting reports of 
disease prevalence in the literature. 
The systematic review of evidence has been proposed and 
is now well-accepted as the ideal method to summarize the 
literature relating to a certain social or healthcare topic (2,3). 
The systematic review can provide a reliable summary of the 
literature to inform decision-makers in a timely fashion. Key 
features of a systematic review include the creation of an a 
priori protocol, clear inclusion criteria, a comprehensive and 
systematic search process, the critical appraisal of studies, and 
a formal process of data extraction followed by methods to 
synthesize, or combine, this data (4). In this way, systematic 
reviews extend beyond the subjective, narrative reporting 
characteristics of a traditional literature review to provide a 
comprehensive, rigorous, and transparent synthesis of the 
literature on a certain topic.
Historically, systematic reviews have predominantly focused 
on the synthesis of quantitative evidence to establish the 
effects of interventions. In the last five years, there has been 
a substantial increase in the number of systematic reviews 
addressing questions of prevalence (Figure 1). However, 
currently there does not appear to be any formal guidance 
for authors wishing to conduct a review of prevalence. 
Consequently, there is significant variability in the methods 
used to conduct these reviews. 
The Joanna Briggs Institute (JBI) and the Cochrane 
Collaboration are evidence-based organizations that were 
formed to develop methodologies and guidance on the 
process of conducting systematic reviews (2,5–8). In 2012, a 
working group was formed within the Joanna Briggs Institute 
to evaluate systematic reviews of prevalence and develop 
guidance for researchers wishing to conduct such reviews. 
The group identified that the major area where prevalence 
reviews were disparate was in their conduct of critical 
appraisal or quality assessment of included studies. For 
example, whilst some reviews used instruments that were 
appropriate for reviews of prevalence data (9,10), others used 
instruments or criteria not designed to critically appraise 
studies reporting prevalence (such as reporting guidelines, 
study design specific tools, or self-developed criteria for their 
review question) (11–13), or refrained from conducting a 
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formal quality assessment altogether (14,15). Therefore, the 
working group sought to address this gap by developing and 
testing a critical appraisal form that could be used for studies 
included in systematic reviews of prevalence data. 
Materials and methods
Developing the Tool 
The working party began by conducting a search for 
systematic reviews of prevalence data to determine how the 
methodological quality of studies included in these reviews 
were assessed. The group then searched for critical appraisal 
tools that have been used to assess studies reporting on 
prevalence data. A number of tools were identified including 
the Joanna Briggs Institute’s Descriptive/Case series critical 
appraisal tool. A non-exhaustive list is shown in Table 1. 
Critical appraisal tools from the Cochrane Collaboration 
and the Critical Appraisal Skills Program (CASP) were 
also identified. 
Although many of these checklists identified important 
criteria, it was felt by the group that none of these tools were 
complete and ideal for use during assessment of quality 
during the systematic review process. Based on a review 
of these criteria and our own knowledge and research we 
developed a tool specifically for use in systematic reviews of 
prevalence data. This tool was initially trialed by the working 
group and refined until it was deemed ready for further 
external review. Details on how to answer each question in 
the tool are available in Appendix 1 and the Joanna Briggs 
Institute guidance on conducting prevalence and incidence 
reviews  (Table 2) (21).
Pilot testing 
A pilot of the tool was conducted during the 2013 Joanna 
Briggs Institute convention in Adelaide during October of 
that year. A workshop was held on systematic reviews of 
prevalence and incidence where attendees were given a cross-
sectional study (22) to appraise with the new tool, along with 
a short survey that was developed to establish the face validity, 
ease of use, acceptability and timeliness (i.e. time taken to 
complete) of the tool, and feedback on areas for improvement 
(23). The questions asked and how they were measured is 
reported in Table 3.
Results
Sixteen workshop participants completed the critical appraisal 
task and survey. Of the 16, 13 participants stated they had 
an academic/research background, 2 said they had a health 
background, and one said they had both. The average time 
spent working in research was 11 years, with the minimum 
being 2.5 years and the maximum experience being 30 years. 
For ease of use of the critical appraisal tool, the mean score on 
the 5-point Likert Scale was 3.63, with the majority (75%) of 
Table 1. Existing critical appraisal tools
Name Number of Criteria Comments
JBI (3) Descriptive/Case series studies appraisal tool 9 Targeted towards specific study designs
Centre for Evidence-Based Management Critical Appraisal of a Survey (16) 12 Targeted towards a specific study design
Loney et al. Critical Appraisal tool for prevalence (17) 8 Designed specifically for studies assessing prevalence 
Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Checklist (18) 22 Targeted towards reporting
National Collaborating Centre for Environmental Health Critical Appraisal 
of Cross-Sectional Studies (19) 11
Addresses external and internal validity as well as 
reporting standards
Hoy et al.’s risk of bias tool (20) 10 Addresses external and internal validity
Figure 1. Number of systematic reviews of prevalence by year of publication identified in a PubMed search
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Table 2. The Joanna Briggs Institute Prevalence Critical Appraisal Tool
Criteria Yes No Unclear Not applicable
1.	 Was the sample representative of the target population?
2.	 Were study participants recruited in an appropriate way?
3.	 Was the sample size adequate?
4.	 Were the study subjects and the setting described in detail?
5.	 Was the data analysis conducted with sufficient coverage of the identified sample? 
6.	 Were objective, standard criteria used for the measurement of the condition? 
7.	 Was the condition measured reliably? 
8.	 Was there appropriate statistical analysis? 
9.	 Are all important confounding factors/subgroups/differences identified and accounted for? 
10.	 Were subpopulations identified using objective criteria? 
participants providing a rating of 4, corresponding to ‘easy’. 
For the acceptability of the tool, the mean score was 4.33, with 
all participants giving either a ranking of 4 (acceptable) or 5 
(very acceptable). For timeliness, the mean score was 3.94, 
with 88% providing a score of 4 (acceptable). Out of all the 
participants, all except 1 viewed the tool as a valid quality 
appraisal checklist for prevalence data (Table 4). 
There were a number of suggestions provided for refinement 
and improvement of the tool. These comments resulted in 
some changes in the order of the questions of the tool and 
the supporting information used to assist in judging criteria, 
although no changes were made to the individual questions.
Discussion
Systematic reviews of prevalence and incidence data are 
becoming increasingly important as decision makers realize 
their usefulness in informing policy and practice. These 
reviews have the potential to better support healthcare 
professionals, policy-makers, and consumers in making 
evidence-based decisions that effectively target and address 
burden of disease issues both now and in to the future.
The conduct of a systematic review is a scientific exercise 
that produces results which may influence healthcare 
decisions. As such, reviews are required to have the same 
rigor expected of all research. The quality of a review, and 
any recommendations for practice that may arise, depends on 
the extent to which scientific review methods are followed to 
minimize the risk of error and bias. The explicit and rigorous 
methods of the process distinguish systematic reviews from 
traditional reviews of the literature (2). 
Systematic reviews normally rely on the use of critical appraisal 
checklists that are tailored to assess the quality of a particular 
study design. For example, there may be separate checklists 
used to appraise randomized controlled trials, cohort studies, 
cross-sectional studies and so on. Prevalence data can be 
sourced from various study designs, even randomized 
controlled trials (11); however, critical appraisal tools directed 
at assessing the risk of bias of randomized controlled trials are 
aimed at assessing biases related to causal effects and hence 
are not appropriate for reviews examining the prevalence 
Table 3. Survey pilot tool
Question Measurement
Ease of use of the tool 5-point Likert scale (1 very difficult, 5 very easy)
Is this a valid tool for prevalence data? Yes/No
Timeliness 5-point Likert Scale (1 very unacceptable, 5 very acceptable)
Acceptability 5-point Likert Scale (1 very unacceptable, 5 very acceptable)
Redundant questions Free text
Comments for improvement Free text 
Table 4. Results from the survey
Experience Ease of tool use Acceptability Time
Number of cases 15 16 15 16
Minimum 2.50 2.00 4.00 2.00
Maximum 30.00 4.00 5.00 5.00
Arithmetic mean 11.37 3.63 4.33 3.94
95.00% lower confidence limit 6.94 3.24 4.06 3.63
95.00% upper confidence limit 15.80 4.00 4.60 4.24
Standard deviation 8.00 0.72 0.49 0.57
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of a condition. For example, criteria regarding the use of an 
intention-to-treat analysis as often seen in critical appraisal 
checklists for randomized controlled trials are not a true 
quality indicator for questions of prevalence.
Due to this, a new tool assessing validity and quality 
indicators specific to issues of prevalence has been developed. 
This checklist addresses critical issues of internal and external 
validity that must be considered when assessing validity of 
prevalence data that can be used across different study designs 
(not just cross-sectional studies but all studies that might 
report prevalence data). The criteria address the following 
issues:
• Ensuring a representative sample.
• Ensuring appropriate recruitment.
• Ensuring an adequate sample size.
• Ensuring appropriate description and reporting of study 
subjects and setting.
• Ensuring data coverage of the identified sample is 
adequate.
• Ensuring the condition was measured reliably and 
objectively.
• Ensuring appropriate statistical analysis.
• Ensuring confounding factors/subgroups/differences are 
identified and accounted for. 
A pilot test of this tool amongst a group of experienced 
healthcare professionals and researchers found that this tool 
had face validity and high levels of acceptability, ease of use and 
timeliness to complete. The initial results of this pilot testing 
are encouraging. This tool now needs to be tested further in 
a larger scale study to assess its other clinimetric properties, 
particularly its construct validity and inter-rater reliability. 
We have developed this tool as we did not feel that any of 
the current checklists identified from our search sufficiently 
addressed important quality issues in prevalence studies. 
Some of the tools [most notably the tool refined by Hoy et 
al. (20)] contain similar questions to our tool but there are 
important differences. For example, we provide a criteria 
regarding sample size which is not included in the Hoy et al. 
checklist. Our tool also has the advantage of being simple, 
easy and quick as shown during the pilot testing. This tool 
will now be incorporated into the next version of the Joanna 
Briggs Institute’s systematic review package. 
Conclusion
Critical appraisal is a pivotal step in the process of systematic 
reviews. As reviews of questions addressing prevalence 
become more well-known, critical appraisal tools addressing 
studies reporting prevalence data are needed. Following a 
search of the literature a new tool has been proposed that can 
be used for studies reporting prevalence data, developed by a 
working party within the Joanna Briggs Institute. The results 
of this pilot study found that this tool was well-accepted by 
users and further refinements have been made to the tool 
based on their feedback. We now put forward this tool for use 
by authors conducting prevalence systematic reviews.
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Implications for policy makers
•	 Until now there has been substantial variability in how 
studies reporting prevalence data are critically appraised. 
The tool proposed within this paper can be considered 
as a valid option for researchers and policy-makers when 
conducting systematic reviews of prevalence. 
•	 This tool guides the assessment of internal and external 
validity of studies reporting prevalence data.
Implications for public
Systematic reviews are of great importance to provide a 
critical summary of the research and inform evidence-
based practice. Prevalence systematic reviews are 
becoming increasingly popular within the research 
community. This article proposes a new tool that can 
be used during the conduct of these types of systematic 
reviews to critically appraise studies to ensure that their 
results are valid. 
Key Messages 
Appendix 1
Prevalence Critical Appraisal Instrument 
The 10 criteria used to assess the methodological quality of 
studies reporting prevalence data and an explanation are 
described below. These questions can be answered either with 
a yes, no, unclear, or not applicable. 
Answers: Yes, No, Unclear or Not/Applicable 
1. Was the sample representative of the target population? 
This  question  relies  upon  knowledge  of  the  broader 
characteristics  of  the  population  of interest. If the study 
is of women with breast cancer, knowledge of at least the 
characteristics, demographics, and medical history is needed. 
The term “target population” should not be taken to  infer 
every  individual  from  everywhere  or  with  similar  disease 
or  exposure  characteristics. Instead,  give  consideration  to 
specific  population  characteristics  in  the  study,  including 
age range, gender, morbidities, medications, and other 
potentially influential factors. For example, a sample may not 
be representative of the target population if a certain group 
has been used (such as those working for one organisation, 
or one profession) and the results then inferred to the target 
population (i.e. working adults). 
2. Were study participants recruited in an appropriate way? 
Recruitment is the calling or advertising strategy for gaining 
interest in the study, and is not the same as sampling. Studies 
may report random sampling from a population, and the 
methods section should report how sampling was performed. 
What source of data were study participants recruited from? 
Was the sampling frame appropriate?  For example, census 
data is a  good example of appropriate recruitment as a good 
census will identify everybody. Was everybody included who 
should have been included?  Were any groups  of  persons 
excluded?  Was the whole population of interest surveyed? 
If not, was random sampling from a defined subset of the 
population employed? Was stratified random sampling with 
eligibility criteria used to ensure the sample was representative 
of the population that the researchers were generalizing to?
3. Was the sample size adequate?
An adequate sample size is important to ensure good 
precision of the final estimate. Ideally we are looking for 
evidence that the authors conducted a sample size calculation 
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to determine an adequate sample size.  This will estimate how 
many subjects are needed to produce a reliable estimate of the 
measure(s) of interest. For conditions with a low prevalence, 
a larger sample size is needed. Also consider sample sizes for 
subgroup (or characteristics) analyses, and whether these are 
appropriate. Sometimes, the study will be large enough (as 
in large national surveys) whereby a sample size calculation 
is not required. In these cases, sample size can be considered 
adequate.  
When there is no sample size calculation and it is not a large 
national survey, the reviewers may consider conducting their 
own sample size analysis using the following formula (24,25):
2
2
(1 )Z P Pn
d
−
=
Where:
n= sample size
Z= Z statistic for a level of confidence
P= Expected prevalence or proportion (in proportion of one; 
if 20%, P= 0.2)
d= precision (in proportion of one; if 5%, d= 0.05)
4. Were the study subjects and setting described in detail? 
Certain  diseases  or  conditions  vary  in  prevalence  across 
different  geographic  regions  and populations  (e.g.  women 
vs.  men,  socio-demographic  variables  between  countries). 
Has  the study sample been described in sufficient detail so 
that other researchers can determine if it is comparable to the 
population of interest to them?
5. Is the data analysis conducted with sufficient coverage of the 
identified sample?
A large number of dropouts, refusals or “not founds” amongst 
selected subjects may diminish a study’s validity, as can low 
response rates for survey studies.
- Did the authors describe the reasons for non-response 
and compare persons in the study to those not in the 
study, particularly with regards to their socio-demographic 
characteristics?
-  Could  the  not-responders  have  led  to  an  underestimate  of 
prevalence  of  the  disease  or condition under investigation?
- If  reasons  for  non-response  appear  to  be  unrelated  to  the 
outcome  measured  and  the characteristics of non-responders 
are comparable to those in the study, the researchers may be 
able to justify a more modest response rate. 
-  Did  the  means  of  assessment  or  measurement  negatively 
affect  the  response  rate (measurement should be easily 
accessible, conveniently timed for participants, acceptable in 
length, and suitable in content). 
6. Were objective, standard criteria used for measurement of 
the condition?
Here  we  are  looking  for  measurement  or  classification 
bias.  Many  health  problems  are  not easily diagnosed or 
defined and some measures may not be capable of including 
or excluding appropriate levels or stages of the health problem. 
If the outcomes were assessed based on existing definitions or 
diagnostic criteria, then the answer to this question is likely to 
be yes. If the outcomes were assessed using observer reported, 
or self-reported scales, the risk of over- or under-reporting 
is increased, and objectivity is compromised. Importantly, 
determine if the measurement tools used were validated 
instruments as this has a significant impact on outcome 
assessment validity.
7. Was the condition measured reliably?
Considerable judgment is required to determine the presence 
of some health outcomes. Having established the objectivity 
of the outcome measurement instrument (see item 6 of this 
scale), it  is  important  to  establish  how  the  measurement 
was  conducted.  Were  those  involved  in collecting data 
trained or educated in the use of the instrument/s? If there 
was more than one data collector, were they similar in terms 
of level of education, clinical or research experience, or level 
of responsibility in the piece of research being appraised?
-  Has the researcher justified the methods chosen?
- Has the researcher made the methods explicit? (For 
interview method, how were interviews conducted?) 
8. Was there appropriate statistical analysis?
As with any consideration of statistical analysis, consideration 
should be given to whether there was a more appropriate 
alternate statistical method that could have been used. The 
methods section should be detailed enough for reviewers 
to identify the analytical technique used and how specific 
variables were measured. Additionally, it is also important to 
assess the appropriateness of the analytical strategy in terms 
of the assumptions associated with the approach as differing 
methods of analysis are based on differing assumptions about 
the data and how it will respond. Prevalence rates found in 
studies only provide estimates of the true prevalence of a 
problem in the larger population. Since some 
subgroups are very small, 95% confidence intervals are 
usually given. 
9. Are all important confounding factors/ subgroups/differences 
identified and accounted for?
Incidence and prevalence studies often draw or report findings 
regarding the differences between groups. It is important that 
authors of these studies identify all important confounding 
factors, subgroups and differences and account for these. 
10. Were subpopulations identified using objective criteria?
Objective criteria should also be used where possible to 
identify subgroups (refer to question 6).
